Welcome to our dedicated page for Nasus Pharma Ltd. SEC filings (Ticker: NSRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Nasus Pharma Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Nasus Pharma Ltd.'s regulatory disclosures and financial reporting.
Capital Point Ltd. reported ownership of 575,129 ordinary shares of Nasus Pharma Ltd., representing 6.35% of the outstanding class based on 9,059,635 shares. The filing shows Capital Point has sole voting and dispositive power over those shares and indicates the holdings were not acquired to change or influence control of the issuer. The report identifies the filer as an Israel-organized entity and provides principal office addresses for both the issuer and filer. The statement is a Schedule 13G disclosure of beneficial ownership and does not include transactions, financial results, or forward-looking commentary.
FAQ
What is the current stock price of Nasus Pharma Ltd. (NSRX)?
What is the market cap of Nasus Pharma Ltd. (NSRX)?
